Sunil Ramaprasad
Interventional Cardiology · Morristown, TNNPI 1679563100
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $67,390 of the $82,717 with a category attached, or 81.5%. Johnson & Johnson accounts for 74.7% of it on its own, with 43 other manufacturers making up the rest. Reporting peaked in 2019 at $37,993 and has fallen 95.6% since, to $1,657 in 2025.
Across 517 payments — averaging $159.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$62K
- Esperion Therapeutics, Inc.$8K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$3K
- Medtronic$1K
- Novo Nordisk$944
- AstraZeneca$888
- plus $7K from 38 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$67,39081%
- Travel & lodging$1,5602%
- Food & beverage$13,27216%
- Education$1960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$60,588
- NEXLIZET$7,744
- NEXLETOL$7,744
- LifeVest$1,500
- Repatha$366
- UPTRAVI$364
- OPSUMIT$364
- BRILINTA$258
- Vascepa$249
- RYBELSUS$230
- Ozempic$226
- Ultreon$151
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$148
- Coronary Orbital Atherectomy System$145
- HeartMate 3 Left Ventricular Dev$142
- FFRangio$140
- Kerendia$125
- UBRELVY$125
- Micra$125
- PRALUENT$121
How this compares
$82,717 in reported general payments places this provider in the 85th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,101 | $1,177,550 |
| XareltoRivaroxaban | 600 | $617,771 |
| EntrestoSacubitril/Valsartan | 420 | $497,308 |
| BrilintaTicagrelor | 153 | $126,055 |
| Repatha SureclickEvolocumab | 130 | $97,002 |
| JardianceEmpagliflozin | 76 | $88,373 |
| FarxigaDapagliflozin Propanediol | 78 | $83,584 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 48 | $11,553 |
| Amiodarone Hcl | 668 | $10,817 |
| ClopidogrelClopidogrel Bisulfate | 1,027 | $10,661 |
| Ranolazine ErRanolazine | 95 | $10,285 |
| Atorvastatin Calcium | 959 | $9,993 |
| EdarbiAzilsartan Medoxomil | 17 | $8,915 |
| NexlizetBempedoic Acid/Ezetimibe | 11 | $8,543 |
| Praluent PenAlirocumab | 14 | $7,698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $157 | $1,177,5501,101 claims |
| Johnson & JohnsonXarelto | $61,768 | $617,771600 claims |
| NovartisEntresto | $422 | $497,308420 claims |
| AstraZenecaBrilinta, Farxiga | $888 | $209,639231 claims |
| Boehringer IngelheimJardiance | $142 | $88,37376 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $14 | $12,97132 claims |
| Esperion Therapeutics, Inc.Nexlizet | $8,024 | $8,54311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Morristown
- Jimmy KerriganNashville$644K
- Kashish GoelNashville$558K
- Brian JeffersonNashville$547K
- Malcolm FosterKnoxville$413K
- Mehul PatelGermantown$382K
- Michael MorseNashville$353K
- Nadia SuttonNashville$344K
- Ayaz RahmanKnoxville$251K
- Samuel HorrNashville$246K
- Joseph WeinsteinMemphis$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.